Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

瑞沁 - NMPA Drug Approval Details

Approvals/NMPA/Henagliflozin Proline Tablets

Approved

化学药品

Henagliflozin Proline Tablets

江苏恒瑞医药股份有限公司🇨🇳 National Medical Products Administration

Approval Date: Dec 31, 2021
Approval ID: 8E25D1cSM5w
Company: 江苏恒瑞医药股份有限公司
Type: 化学药品

Approval Details

Approval Id: 8E25D1cSM5w
Approval Number: 国药准字H20210052
Generic Name: 脯氨酸恒格列净片
Generic Name En: Henagliflozin Proline Tablets
Trade Name: 瑞沁
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 5mg(按C22H24ClFO7计)
Reg Date: 2021-12-31
Company Name: 江苏恒瑞医药股份有限公司
Company Address: 连云港经济技术开发区黄河路38号
Production Company Name: 江苏恒瑞医药股份有限公司
Production Company Address: 连云港经济技术开发区黄河路38号
Company Detail Path: /organization/f261c0866eb0c56c/hengrui-pharma
Production Company Detail Path: /organization/f261c0866eb0c56c/hengrui-pharma

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Dec 31, 2021

Approval ID

8E25D1cSM5w

Type

化学药品

Back to NMPA Approvals